ORIC

Oric Pharmaceuticals Inc

ORIC, USA

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

https://www.oricpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ORIC
stock
ORIC

ORIC Pharmaceuticals (ORIC) Surges as Intriguing ESMO Asia Data for Enozertinib Prompts Wells Fargo to Assign Higher Value Yahoo Finance UK

Read more →
ORIC
stock
ORIC

Frazier Life Sciences Management L.P. Sells 344,859 Shares of Oric Pharmaceuticals, Inc. $ORIC MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$19.9167

Analyst Picks

Strong Buy

10

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.28

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-8.01 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-7.56 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.06

Low 1

High 0.3

Investors

* Institutions hold a combined 89.34% of the total shares of Oric Pharmaceuticals Inc

1.

Nextech Invest, Ltd.

(7.3748%)

since

2025/06/30

2.

VR Adviser, LLC

(6.7923%)

since

2025/06/30

3.

Viking Global Investors LP

(6.7674%)

since

2025/06/30

4.

Pfizer Inc

(5.5356%)

since

2025/06/30

5.

SR ONE CAPITAL MANAGEMENT, LP

(4.6487%)

since

2025/06/30

6.

Alkeon Capital Management, LLC

(4.6375%)

since

2025/06/30

7.

NEA Management Company, LLC

(4.2406%)

since

2025/06/30

8.

BlackRock Inc

(4.1988%)

since

2025/06/30

9.

Column Group LLC

(3.6457%)

since

2025/06/30

10.

Vivo Capital, LLC

(3.2192%)

since

2025/06/30

11.

Vanguard Group Inc

(3.2173%)

since

2025/06/30

12.

Point72 Asset Management, L.P.

(2.9351%)

since

2025/06/30

13.

T. Rowe Price Associates, Inc.

(2.8448%)

since

2025/06/30

14.

FMR Inc

(2.5432%)

since

2025/06/30

15.

ACAP Strategic A

(2.292%)

since

2025/06/30

16.

First Turn Management LLC

(2.0695%)

since

2025/06/30

17.

Vanguard Total Stock Mkt Idx Inv

(1.9519%)

since

2025/07/31

18.

SILVERARC CAPITAL MANAGEMENT, LLC

(1.8542%)

since

2025/06/30

19.

Balyasny Asset Management LLC

(1.8304%)

since

2025/06/30

20.

MPM Oncology Impact Management LP

(1.7806%)

since

2025/06/30

21.

State Street Corp

(1.6805%)

since

2025/06/30

22.

EcoR1 Capital, LLC

(1.666%)

since

2025/06/30

23.

Fidelity Growth Compy Commingled Pl S

(1.3491%)

since

2025/07/31

24.

iShares Russell 2000 ETF

(1.1277%)

since

2025/08/31

25.

Eventide Healthcare & Life Sciences I

(0.9796%)

since

2025/06/30

26.

T. Rowe Price Health Sciences

(0.9534%)

since

2025/07/31

27.

US Small-Cap Growth II Equity Comp

(0.9412%)

since

2025/06/30

28.

T. Rowe Price New Horizons

(0.8034%)

since

2025/07/31

29.

Franklin Biotechnology Discv A(acc)USD

(0.7557%)

since

2025/08/31

30.

Fidelity Growth Company Fund

(0.7448%)

since

2025/07/31

31.

SPDR® S&P Biotech ETF

(0.535%)

since

2025/08/31

32.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5109%)

since

2025/07/31

33.

Fidelity Small Cap Index

(0.4644%)

since

2025/06/30

34.

Meridian Contrarian Legacy

(0.381%)

since

2025/06/30

35.

JPMorgan Small Cap Value I

(0.3775%)

since

2025/07/31

36.

Franklin Biotechnology Discovery A

(0.374%)

since

2025/07/31

37.

Victory Science & Technology

(0.3725%)

since

2025/06/30

38.

Meridian Small Cap Growth Legacy

(0.3221%)

since

2025/06/30

39.

ArrowMark Small Cap Gro

(0.3221%)

since

2025/06/30

40.

iShares Biotechnology ETF

(0.2972%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.3703

Latest Release

Date

2025-09-30

EPS Actual

-0.33

EPS Estimate

-0.4

EPS Difference

0.07

Surprise Percent

17.5%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.